Insulet Corporation
(NASDAQ: PODD), the leader in tubeless insulin pump technology, today
announced that the Company has received 510(k) clearance from the
U.S. Food and Drug Administration (FDA) for the next-generation
OmniPod(R) Insulin Management System. The new OmniPod insulin pump is
more than one-third smaller and one-quarter lighter than the original
model, while maintaining the same 200-unit insulin reservoir capacity
and easy-to-use features. In addition to the smaller, lighter Pod,
the new OmniPod System includes an updated Personal Diabetes Manager
(PDM) that also features a series of enhancements.
